Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: A comprehensive review by Utian, Wulf H
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
Health and Quality of Life Outcomes
Open Access Review
Psychosocial and socioeconomic burden of vasomotor symptoms in 
menopause: A comprehensive review
Wulf H Utian*
Address: North American Menopause Society, 5900 Lander Brook Drive, Mayfield Heights, OH 44124, USA
Email: Wulf H Utian* - utian@menopause.org
* Corresponding author    
Abstract
Many women experience vasomotor symptoms at or around the time of menopause. Hot flushes
and night sweats are considered primary menopausal symptoms that may also be associated with
sleep and mood disturbances, as well as decreased cognitive function. All of these symptoms may
lead to social impairment and work-related difficulties that significantly decrease overall quality of
life. Hot flushes have shown a great deal of variability in their frequency and severity in women. In
some women, hot flushes persist for several months; in others, they may last for more than 10
years. Traditionally vasomotor symptoms were reported to begin 5 to 10 years prior to the
cessation of the final menstrual cycle, corresponding with the initial decline in circulating gonadal
hormones; however, night sweats in particular most often begin in perimenopause. The
pathogenesis of hot flushes has not yet been fully elucidated, but the circuitry involving estrogen
and neurotransmitters, norepinephrine and serotonin specifically, are hypothesized to play a major
role in the altered homeostatic thermoregulatory mechanisms underlying these events.
Menopause-associated vasomotor symptoms are associated with significant direct and indirect
costs. Overall costs of traditional pharmacotherapy or complementary and alternative medicine
modalities, including over-the-counter treatments and dietary supplements, for managing
menopause-related vasomotor symptoms are substantial and include initial and follow-up physician
visits and telephone calls. Additional costs include laboratory testing, management of adverse
events, loss of productivity at work, and personal and miscellaneous costs. Pharmacoeconomic
analyses, including those that consider risks identified by the Women's Health Initiative, generally
support the cost-effectiveness of hormonal therapy for menopause-associated vasomotor
symptoms, which have been the mainstay for the management of these symptoms for more than
50 years. However, because many women now want to avoid hormone therapy, there is a need
for additional targeted therapies, validated by results from controlled clinical trials that are safe,
efficacious, cost-effective, and well tolerated by symptomatic menopausal women.
Review
Menopause is characterized by physiologic and psychoso-
cial changes in a woman's life. Menopause may be associ-
ated with vasomotor symptoms (VMS; hot flushes [also
referred to as hot flashes] and night sweats), bone loss,
urogenital atrophy, urinary tract infections and
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incontinence, increased cardiovascular risk, somatic
symptoms, sexual dysfunction and decreased libido, and
loss of skin elasticity. VMS, and the sleep and mood dis-
turbances that often result from them, can have a signifi-
cant negative impact on overall quality of life (QOL) for a
substantial number of women. The impact of VMS has
gained in importance as the lifespan of women has
increased throughout the world since women can expect
to spend a significant portion of their lives after meno-
pause. This period should be a highly productive time for
women, and maintaining functional ability and a good
QOL is of utmost importance. Accordingly, it is important
to understand the economic and QOL impacts of meno-
pausal VMS as well as the most recent pharmacoeconomic
analyses of different approaches to managing symptoms.
Thus, the aims of this paper are to briefly review the epi-
demiology of VMS, describe what is known about the
physiologic basis of these symptoms, and examine the
global and health-related quality of life (HRQOL) effects
of VMS in women, with a focus on psychosocial and eco-
nomic impairments, and costs associated with treatments.
Epidemiology of VMS
Prevalence and risk factors
Recent US Census Bureau statistics indicate that approxi-
mately one third of women are older than 50 years of age
[1]. It is estimated that 75% of women in this age group
will experience hot flushes, a value supported by a recent
longitudinal study of 454 women who were followed
from premenopause to postmenopause [2]. Thus, in the
United States alone, there are approximately 40 to 50 mil-
lion women who experience hot flushes [1]. Worldwide,
between 50% and 85% of women (approximately 360
million) older than 45 years of age experience hot flushes
[3]. The prevalence of hot flushes varies widely across
populations and is strongly influenced by culture and eth-
nicity. In the United States, the Study of Women's Health
Across the Nation (SWAN) surveyed more than 16,000
women and found that the prevalence of hot flushes was
highest among African Americans (46%), followed by
Hispanics (34%), whites (31%), Chinese (21%), and Jap-
anese (18%) [4]. In other parts of the world, rates of hot
flushes vary widely as well, with the lowest prevalence
observed in China (10%) and other Asian nations [5].
Many attempts have been made to identify demographic
characteristics associated with a significantly increased
risk of hot flushes. For many years, low body mass index
(BMI) and race were considered significant predictors of
VMS, with thin, white women believed to at the highest
risk for hot flushes. More recent findings have suggested
that high BMI and African American race are associated
with a higher risk of VMS. This shift may be related to bet-
ter sampling of the general population by major clinical
trials because, traditionally, white middle-class women
participated in clinical trials that often did not include
women from other ethnic groups. The multiethnic SWAN
not only demonstrated a link between an elevated BMI
(≥27 kg/m2) and hot flushes [4], but an increased preva-
lence in African American women, as mentioned. Ongo-
ing studies continue to investigate potential predictors of
hot flushes. Smoking, maternal history, history of pre-
menstrual complaints, elevated basal core body tempera-
ture, low physical activity, low socioeconomic status, and
low levels of estrogen and high levels of luteinizing and
follicle-stimulating hormones prior to the menopausal
transition have all been associated with an increased risk
of hot flushes [4,6-8].
Timing of hot flushes
The timing and frequency of hot flushes have been
reviewed by several researchers [9]. SWAN demonstrated
that hot flushes occur earlier than previously believed and
may become less frequent and less intense as menopause
progresses. SWAN data indicated that VMS were more fre-
quently reported by women in late perimenopause with a
relative risk for hot flushes at 1.0 during premenopause
(the 1 or 2 years prior to menopause), 2.06 during early
perimenopause (the early menopausal transition), 4.32
during late perimenopause (the late menopausal transi-
tion), and 2.81 during postmenopause [4]. The frequency
of hot flushes varies but tends to remain consistent for an
individual [10]. Many women have hot flushes on a daily
basis, some as frequently as every hour, whereas others
have VMS infrequently (ie, weekly or monthly) [10]. The
majority of women experience hot flushes for 6 months to
2 years, with the highest number of women reporting
symptoms during the first 2 postmenopausal years [9,10].
However, in another study, 26% of women reported hav-
ing hot flushes for 6 to 10 years, whereas 10% have had
VMS for more than 10 years [11].
Pathophysiology
The cause of hot flushes has yet to be determined because
of the limited research focus in this therapeutic area. Hot
flushes are believed to result from the brain's response to
diminished hormones and hormonal fluctuations that
occur during the menopausal transition. Ovarian hor-
mones have been shown to influence thermoregulatory
mechanisms that regulate temperature homeostasis in the
hypothalamus. The neurotransmitters serotonin and
norepinephrine play a role in modulating core body tem-
perature, neurochemical messaging, and peripheral vascu-
lature [12]. Kronenberg and colleagues were the first
investigators to document cardiovascular, temperature,
hormonal, and autonomic parameters with hot flushes
and link them with thermoregulatory mechanisms [13],
with more recent mechanistic information published by
Freedman [14] and Deecher et al. [12].Health and Quality of Life Outcomes 2005, 3:47 http://www.hqlo.com/content/3/1/47
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Effects of associated VMS on QOL
Perceived QOL is difficult to measure and there is no uni-
versal agreement on how it should be quantified. Objec-
tive measurements of health status (often referred to as
HRQOL) may not capture the patient's perception of
overall life satisfaction. QOL can be defined as a reflection
of an individual's belief about functioning and achieve-
ment. HRQOL may be viewed as the individual's percep-
tion regarding her physical, cognitive, and mental health
as well as social situation [15]. Assessments of overall
QOL for menopausal women must include consideration
of somatic symptoms (hot flushes, night sweats, urogeni-
tal atrophy), psychological symptoms (depression, mood
swings, irritability, anxiety), and life circumstances (func-
tion in the workplace). Thus, overall QOL may include
four major factors: occupational, health-related, sexual,
and emotional [15]. Consideration of HRQOL is also
influenced by women's increased risk of multiple chronic
diseases associated with menopause, including osteope-
nia, osteoporosis and related fractures, and cardiovascular
disease [16].
VMS-related effects on QOL
VMS can have a significant negative impact on QOL in
younger and older women, contributing to physical as
well as psychosocial impairment (Table 1). Becoming
flushed and sweating profusely in a social or work-related
situation may cause extreme anxiety for many women and
lead to social isolation [17].
Although it is generally accepted that VMS are troubling to
many women and adversely impact their QOL, these
effects are difficult to quantify because of the many factors
that contribute to overall QOL satisfaction. For example,
an objective of the Women's Health Initiative (WHI) was
to determine whether hormonal therapy (HT) could
reverse impaired HRQOL in 16,608 women aged 50 to 79
years. Results from this analysis indicated that estrogen
plus progesterone did not yield any significant benefits in
any of the HRQOL outcomes when compared with pla-
cebo over 3 years of follow-up [18]. However, this investi-
gation did not examine global QOL in relation to VMS as
an a priori outcome, and the women studied were not
only excluded if the investigators felt they were having sig-
nificant VMS that would interfere with long-term study
involvement, but were older than those who typically
have VMS and use HT. Another limitation was the use of
a QOL questionnaire that may have been inadequate for
determining the global impact of VMS. More recently, a
new QOL scale has been designed specifically for the per-
imenopausal population [19]: The Utian Quality of Life
(UQOL) Scale evaluates occupational, health, emotional,
and sexual QOL. This 23-item assessment should increase
the reliability of QOL measurement in perimenopausal
and postmenopausal women.
The physiologic changes associated with menopause
often result in increased anxiety and stress. These feelings
may arise from sleep deprivation, mood swings, and
unpredictable hot flushes. Before menopause, most
women have a monthly hormonal rhythm. When the
cycle becomes disrupted by erratic hormonal fluctuations,
a woman's sense of well-being can be disturbed. These
changes also tend to occur at a time when women are
more likely to experience other life changes, including
divorce, widowhood, children leaving home, concerns
about aging parents, and other caregiving issues. Self-
image is another important variable, and women with
poor self-images have more flush-related distress [20]. In
combination, these factors may each contribute to a
reduced global QOL as well as decreased work productiv-
ity and difficulties with personal and social relationships.
A large number of studies have documented the negative
impact of menopause on QOL. Ledesert and colleagues
studied a cohort of 289 women aged 45 to 52 years who
were no longer menstruating and reported lower HRQOL
on several measures of the Nottingham Health Profile
compared with values for menstruating women [21]. A
population-based study evaluated the effects of various
medical conditions on work impairment in more than
16,500 individuals [22]. Menopause was one of the fac-
tors associated with significant work limitations. The
impact of VMS on HRQOL has also been studied by Bob-
ula and colleagues, who evaluated 1,655 healthy, nonhys-
terectomized, postmenopausal women ranging in age
Table 1: Vasomotor Symptoms and Related Psychosocial 
Impairment During the Menopausal Transition
Hot flushes
Night sweats
Sleep disturbances
Insomnia
Sleep apnea
Mood swings
Irritability
Sadness
Tension
Cognitive deficits
Poor concentration
Verbal memory problems
Social impairment
Disruption of family relationships
Social isolation
Work-related difficulties
Reduced productivity
Other Quality-of-life impairment
Embarrassment
Anxiety
FatigueHealth and Quality of Life Outcomes 2005, 3:47 http://www.hqlo.com/content/3/1/47
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from 40 to 65 years who were not receiving HT [23]. Their
results indicated a significant correlation between moder-
ate to severe hot flushes and decreased QOL. Women with
moderate to severe hot flushes had significantly poorer
scores than women with no hot flushes on four of the
eight 36-item Short Form Health Survey (SF-36) subscales
(vitality, bodily pain, social function, and role limita-
tions-emotional), the mental composite score, and the
Women's Health Questionnaire (WHQ), with pro-
nounced differences for VMS, sleep problems, sexual
behavior, and somatic symptoms. Women with moderate
to severe hot flushes also had significantly poorer scores
than women with mild hot flushes on two of the eight SF-
36 subscales (vitality and social function) and five of the
nine WHQ domains, including VMS, sleep problems, sex-
ual behavior, somatic symptoms, and depressed mood.
Finally, women with mild hot flushes had significantly
worse scores than women with no hot flushes on two of
the eight SF-36 subscales (vitality and role limitations-
emotional) and on the WHQ for VMS, sleep problems,
somatic symptoms, memory/concentration, and men-
strual symptoms.
Impact of VMS on sleep, mood, and cognitive function
Despite the lack of agreement in the medical literature
about the relationship between VMS on sleep quality,
mood variability, and cognitive function, these symptoms
are, in fact, primary complaints of menopausal women to
their healthcare practitioners; as such, they are addressed
in this review.
Sleep disturbances
The causes of menopause-related sleep disturbances are
controversial. It has been suggested that problems with
sleep may occur in older women independently of meno-
pause. For example, nocturia increases with age and may
disturb sleep [24]. Depression, stress, and other factors
(eg, restless leg and other periodic limb movement syn-
dromes) may also contribute to sleep disturbances in
these patients [25].
Sleep disturbances also have been specifically related to
hormonal changes that trigger hot flushes or night sweats,
independent of age. A National Sleep Foundation poll of
1,000 women between the ages of 30 and 60 years found
that 36% of perimenopausal, postmenopausal, and
oophorectomized women experienced hot flushes during
the night [26]. In this study, 44% of women who experi-
enced VMS while sleeping were perimenopausal versus
28% of women who were postmenopausal. The poll also
showed that menopausal and postmenopausal women
slept less than premenopausal women. According to the
National Sleep Foundation, women with night sweats
experienced an average of three occurrences per week.
These events disrupted sleep and led to daytime irritability
[26].
Menopause-related VMS also may be associated with
insomnia and disordered breathing at night. More peri-
menopausal and postmenopausal women than menstru-
ating women have difficulty falling asleep, staying asleep,
and achieving refreshing sleep [26]. Insomnia symptoms
in women in the various stages of menopause include dif-
ficulty falling asleep (29%) and early awakening with an
inability to fall back to sleep (21%). Respiratory abnor-
malities also may contribute to sleep disturbances in men-
opausal women. Results from a study of 589 women
indicated that those in the menopausal transition were at
a greater risk for complaints of sleep apnea and hypopnea
than were younger women [27]. Postmenopausal women
had a 2.6-to 3.5-fold greater rate of sleep-disordered
breathing than their premenopausal counterparts [27].
Because sleep complaints are part of menopause-associ-
ated VMS, disordered breathing is often overlooked as a
potential cause of menopause-associated sleep distur-
bance [27]. Although these and other results have sug-
gested a correlation between the occurrence of hot flushes
and sleep complaints in menopausal women, only a few
studies have employed objective methods for sleep evalu-
ation (eg, polysomnography, actigraphy, quantitative
electroencephalographic analysis). Results from these
assessments have indicated that hot flushes correlate with
the occurrence of objectively demonstrable sleep disrup-
tion in at least some women [28].
Inadequate and unrefreshing sleep can have many conse-
quences. Over time, disruption of sleep secondary to hot
flushes and/or night sweats leads to chronic sleep deficits,
significantly impaired alertness and mental acuity, care-
lessness, forgetfulness, and decreased work productivity.
In some cases, night sweats can drench bedclothes and
sheets, further disrupting sleep and necessitating a change
of clothes and covers, which can also disturb the sleep of
the individual's bed partner. Thus, lack of sleep, tiredness,
and irritability can affect daytime productivity as well as
familial and social relationships.
Mood
Menopause-associated changes in mood may result from
a wide range of variables, including elevated sensitivity to
environmental events secondary to decreased hormonal
levels, changes in socioeconomic and/or marital status,
culture, lifestyle factors, level of education, and history of
depressive symptoms [29,30]. Longitudinal and cross-sec-
tional studies carried out to date have not indicated a con-
sistent relationship between the menopausal transition
and increased risk of mood disorders [31,32]. However,
results from the prospective population-based Melbourne
Women's Midlife Health Project, which followed 438Health and Quality of Life Outcomes 2005, 3:47 http://www.hqlo.com/content/3/1/47
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women for 11 years and used the Center for Epidemio-
logic Studies Depression Scale to measure depression,
indicated that depression scores were highest for women
who were in the menopause transition stage (ie, had not
reached their final menstrual period) or who had experi-
enced surgical menopause. Current use of HT was associ-
ated with lower Center for Epidemiologic Studies
Depression Scale scores (ie, less severe depressive symp-
toms) in this cohort [33]. These epidemiologic results are
consistent with those from a small-scale clinical trial that
demonstrated the significant benefit of short-term HT in
perimenopausal women with depression [34]. It is impor-
tant to note that many studies investigating mood and
VMS have used depression scales. There are important dis-
tinctions between mood variability and major depression.
It is incorrect to interpret the results from depression and
simply extrapolate these findings to mood. Hopefully,
new studies will address this issue and develop specific
scales to delineate the impact of VMS on mood.
Cognitive decline
Memory impairment is directly related to hot flushes in
women who have undergone oophorectomy, but natural
menopause itself does not necessarily result in significant
cognitive dysfunction [35]. During a hot flush, blood flow
decreases in the hippocampus, possibly impairing mem-
ory and cognition [35]. It has been suggested that such
reductions in blood flow may contribute to the decreased
mental clarity and short-term verbal memory problems
experienced by many perimenopausal and postmenopau-
sal women [35]. The importance of estrogen in cognition
has been demonstrated by Jacobs and colleagues, who
measured cognitive function and verbal memory in 727
older women (average age, 74.2 years). Study results dem-
onstrated that cognitive test scores and verbal memory
were superior in the women who received HT compared
with those who did not [36].
Costs associated with VMS and their treatment
In the year 2000, there were approximately 50 million
women aged 45 to 60 years in the United States; as life
expectancy increases, that number will increase [1]. Many
of these women will use the health care system for pre-
menopausal, perimenopausal, and postmenopausal
needs. These requirements pose a high economic burden
on the women themselves and on the health care system
(Figure 1).
Determining the cost-effectiveness of treatments aimed at
relieving VMS is complex. Analysis must consider the
direct costs of treatment, costs associated with treatment-
related adverse events, and the health care costs saved
with effective therapy [37,38]. Cost-utility analysis of
treatment for VMS also considers the impact of treatment
on improvements in QOL associated with the alleviation
of symptoms. This impact of treatment is expressed in
quality-adjusted life years (QALYs) [39].
Since the publication of results from the WHI in 2002,
therapy for menopausal symptoms has undergone a dra-
matic transition. A marked decline has been seen in pre-
scriptions for oral estrogen and HT. Prescriptions for oral
estrogens declined from 56.8 million in 2001 to 37.2 mil-
lion in 2003. The respective values for oral HT were 24.0
and 10.3 million [40]. However, the pendulum has swung
from fear to a greater understanding of the risks and ben-
efits of HT [41].
Costs incurred for the management of menopause-related
VMS include visits to physicians; follow-up visits and tel-
ephone calls for the management of medication-related
side effects and changes in medication; self-prescribed
over-the-counter remedies, including complementary
alternative medications (CAMs); HT; laboratory tests; lost
productivity at work; personal costs for hygiene-related
supplies; energy costs for the increased use of air condi-
tioning; and extra laundry requirements for clothing and
bed sheets soiled with sweat. A recent Gallup poll of men-
opausal women showed that hot flushes and night sweats
were the first-and second-ranked symptoms that
prompted physician visits. Among the women surveyed,
70% complained of hot flushes, 68% complained of night
sweats, 50% had mood changes and moodiness, and 49%
experienced insomnia and sleeplessness [42]. The costs
associated with many of these symptoms have not been
quantified, but they undoubtedly result in a significant
burden for the women who experience them.
Before seeking medical advice at the onset of VMS,
women are likely to obtain information from their peers,
family members, or the Internet. In many cases women
resort to self-diagnosis and treatment. They may combine
over-the-counter drugs with medications prescribed for
other conditions (eg, analgesics for headache; anxiolytics
and antidepressants for anxiety, tension, and mood
changes; sedatives/hypnotics for insomnia). Most of these
treatments fail to provide significant relief of VMS, and
many women ultimately consult their physicians after
these remedies fail. Physician visits for VMS include an
initial visit to a primary care physician and, potentially,
follow-up visits to a gynecologist or CAM specialist. Sub-
sequent visits and telephone calls are often needed for
medication adjustment, laboratory testing, and managing
side effects. In addition, women may seek counseling
from a psychologist or psychiatrist for mood changes,
insomnia, and difficulties with family and social interac-
tions. Women may also visit a neurologist for relief from
headaches and/or help with cognitive deficits. All of these
factors add to the economic burden of VMS.Health and Quality of Life Outcomes 2005, 3:47 http://www.hqlo.com/content/3/1/47
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Flowchart of factors affecting management costs of menopause related vasomotor symptoms Figure 1
Flowchart of factors affecting management costs of menopause related vasomotor symptoms.
Menopause-Related Vasomotor Symptoms 
o Sleep disturbances 
o Mood swings 
o Cognitive deficits 
o Reduced quality of life 
¾ Work-related disability 
¾ Social isolation 
¾ Embarrassment
Hygiene-related personal 
costs
Increased Economic Burden 
Visits to medical specialists and 
alternative medicine practitioners 
Physician visits 
Prescription and OTC 
medication
Laboratory fees 
Follow-up visits/phone calls 
for medication side effects
Loss of productivity at 
home and work 
Increased energy usage 
for air conditioning and 
laundry Health and Quality of Life Outcomes 2005, 3:47 http://www.hqlo.com/content/3/1/47
Page 7 of 10
(page number not for citation purposes)
Economic burden of therapy for symptom 
resolution
Hormonal therapy
The economic burden of VMS management remains high
even with the use of HT. Costs associated with HT include
one or two visits for diagnosis and medication prescrip-
tion as well as follow-up visits and telephone calls to man-
age side effects and evaluate the efficacy of therapy.
Serious, but rare, adverse events associated with HT can
lead to exceptionally high acute and chronic costs [43].
Evaluation and management of more common transient
adverse events, including vaginal and uterine bleeding,
breast discomfort, and breast nodularity, can also add sig-
nificantly to the overall cost of HT for menopause-related
symptoms. Approximately one third of patients who use
HT switch to another form of therapy or make medication
adjustments because of adverse events or compliance
problems, increasing the overall cost of therapy [43].
Despite the complexities associated with determining the
cost-effectiveness of HT for the treatment of women with
menopause, several pharmacoeconomic analyses support
the use of such treatment. Results from an early evaluation
by Weinstein suggested that HT was cost-effective in men-
opausal women with prior hysterectomy or osteoporosis,
but not in asymptomatic women with an intact uterus.
The evaluation included information about the risks of
endometrial cancer, uterine bleeding, and gallbladder dis-
ease as well as the benefits associated with the relief of
menopausal symptoms and prevention of osteoporosis
and fractures [44].
Although long-term continuous-combined HT (0.625
mg/day of conjugated estrogens plus 2.5 mg of medroxy-
progesterone [CEE/MPA]) has been associated with the
potential for increased health risks in some women, ther-
apy limited to ≤5 years is no doubt beneficial for decreas-
ing VMS, somatic symptoms, and resultant sleep and
mood disturbances in women who experience bother-
some menopausal symptoms. Moreover, short-term, low-
dose therapy may minimize the risk of adverse effects
associated with longer-term HT [45]. Botteman and
colleagues compared the cost-effectiveness of short-term
CEE/MPA 0.625/2.5 mg against that of norethindrone
acetate 1 mg and ethinyl estradiol 5 µg (NA/EE), another
continuous-combined HT with a different side-effect pro-
file, and no interventional therapy for the management of
moderate to severe VMS [45]. Anticipated 1-year baseline
costs for the management of VMS included drug acquisi-
tion costs ($357 for NA/EE vs $474 for CEE/MPA), initia-
tion of therapy requiring two physician visits ($132), HT-
related breakthrough bleeding requiring endometrial
biopsy and associated visits and laboratory testing ($345),
or spotting requiring a telephone call to the physician
($16), and two physician visits for VMS plus clonidine
therapy ($162; Table 2) [45]. Results from this analysis
indicated that NA/EE was less expensive and more effec-
tive than CEE/MPA in QALYs. The cost-effectiveness of
NA/EE was greater for patients with severe VMS than those
with mild symptoms. NA/EE also was more cost-effective
than no treatment, unless the symptoms were so mild that
the discomfort of spotting or bleeding (the most common
significant adverse effects of short-term HT) offset the
QOL improvements associated with HT [45]. It also
should be noted that the health risks associated with
shorter-term (1 to 5 years) HT for the treatment of VMS
are not known. Another trial evaluating NA/EE against
CEE/MPA 0.625/2.5 mg or no therapy in premenopausal
and perimenopausal women indicated that NA/EE is cost-
effective as first-and second-line therapy [46]. Results
from this study showed that NA/EE increased costs and
QALYs compared with CEE/MPA and no therapy. Despite
the increase in direct costs over no therapy and CEE/MPA,
the cost effectiveness of NA/EE compared to no therapy is
based on a decrease in the cost of treating menopausal
symptoms, vaginal bleeding, and hip fractures and
Table 2: Baseline Costs for a Pharmacoeconomic Model of Vasomotor Symptoms
Drug acquisition costs
Norethindrone acetate/ethinyl estradiol $357
Conjugated estrogen/medroxyprogesterone $474
Therapy initiation
Two physician visits $132
Breakthrough bleeding at 3 months (or continued spotting at 6 months)
Endometrial biopsy $198
Pathology and laboratory fees $147
Telephone call to physician
Spotting at 3 months $16
Moderate to severe vasomotor symptoms
Two physician visits $132
90-day supply of clonidine $31
Adapted with permission from Botteman et al. [45].Health and Quality of Life Outcomes 2005, 3:47 http://www.hqlo.com/content/3/1/47
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assumes a substantial increase in compliance compared to
CEE/MPA as a result of improved control of bleeding with
NA/EE. Results from a study reported by Ohsfeldt et al.
indicated that the 1-year cost of HT for treating VMS was
approximately $300 greater than the cost associated with
no treatment [47]. It is not clear how results from this
Canadian analysis would apply to the United States since
health care is much less expensive in that country.
As noted, the published results from the WHI have dra-
matically reduced the use of estrogen and HT by meno-
pausal women. Results from the WHI prompted
reanalysis of the cost-effectiveness of HT by investigators
at the Stockholm School of Economics. Generalization of
results from this analysis may be limited because Sweden
has a national socialized medical system. However, the
authors suggest that HT remains a cost-effective therapeu-
tic strategy for women with menopausal VMS compared
with no therapy [47].
SSRIs and SNRIs
Selective serotonin reuptake inhibitors (SSRIs) and serot-
onin-norepinephrine reuptake inhibitors (SNRIs) have
received increased attention for the management of VMS
in nondepressed menopausal women [48]. As yet, there
have been no pharmacoeconomic analyses of any agents
in these classes for this indication. Results from a recent
systematic review of published economic evaluations of
interventions for depression indicated that SSRIs and
SNRIs are more cost-effective than older antidepressant
medications (eg, tricyclic antidepressants) owing to their
greater efficacy and decreased side-effect profile [49].
Other prescription medications
Other prescription medications approved for use in con-
ditions not associated with menopause-related VMS have
demonstrated varying degrees of efficacy [48]. The eco-
nomic advantage for some of these medications is that
they have been on the market for a number of years. Given
the understanding that the VMS are the result of a dys-
function in thermoregulatory circuitry, new nonhormo-
nal therapies that selectively target the serotonin and
norepinephrine pathways, without the involvement of
other pathways, seem likely to become the next genera-
tion of care for the management of VMS.
CAM treatments
Many symptomatic menopausal women are likely to treat
themselves before consulting a medical practitioner,
thinking that "natural" products are safer and the ingredi-
ents more pure than synthetic agents. Cost analysis was
carried out for CAM treatments that women would com-
monly find through a basic search on the Internet using
the terms complementary medicine and hot flash as search
parameters. The most common CAM treatments that
emerged were products containing individual and com-
pounded formulas of herbs, isoflavones, and dietary sup-
plements that promised to alleviate menopause-related
hot flushes and night sweats, irritability, sleeplessness,
mood swings, weight gain, headaches, insomnia, depres-
sion, menstrual irregularities, fatigue, and loss of sexual
desire. These formulations also claim to promote mental
clarity, increase energy levels, and improve physical per-
formance [50-53]. The initial cost of a single product
ranged from $19.95 to $58.00 per month (Table 3). A key
limitation in the analysis of these products is that their
clinical efficacy has generally not been documented by
results from controlled clinical trials. It has also been
noted that any benefits associated with herbal supple-
ments may occur more slowly than those achieved with
traditional medications [54]. Comparison of 1-year costs
of CAM treatments versus HT indicated that three of seven
alternative treatments were more expensive than tradi-
tional therapy (Table 3).
Table 3: Complementary and Alternative Medicine Costs Over 6 Months
Product Main Ingredients Cost ($US) 
at 1 Month
Cost ($US) 
at 3 Months
Cost ($US) 
at 6 Months
Femforte® Black cohosh, soy isoflavones, androstenedione, chaste berry 58.00 174.00 348.00
MACA750™ Organic maca root 19.95 59.85 119.70
Promensil™ Red clover 24.95 64.90 129.80
Remifemin® Black cohosh extract equivalent to 20 mg dried Cimicifuga rhizome 49.99 78.98 157.96
Sleep & Slim™ L-glutamine, L-lysine HCl, magnesium citrate, L-ornithine, glysine, L-
arginine, collagen, vitamin B6 (pyroxidine HCl), L-carnitine, vitamin B3 
(niacin), aloe vera, ascorbic acid, citric acid, sodium benzoate, 
potassium sorbate, carrageenan
49.95 149.85 299.70
Effisoy™ AglyMax: fermented soy germ extract 29.95 79.35 149.75
Hot Flash, Non-GMO Soy Geneistein-rich soy concentrate, black cohosh root extract, dong 
quai root extract, licorice root extract, vitex berry extract
45.98 137.94 275.88
Note: Three-and 6-month costs that are lower than 3 and 6 times the 1-month costs for certain items reflect bulk prices for the items.Health and Quality of Life Outcomes 2005, 3:47 http://www.hqlo.com/content/3/1/47
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Conclusion
Menopause-related VMS are very common and can be
associated with a high patient and societal burden. These
symptoms result in high direct and indirect costs and sig-
nificantly reduced QOL. Current treatments for VMS
include HT, prescription medications developed for other
indications, and CAM treatments. Short-term HT has been
shown to be cost-effective for the management of VMS,
but the publicity given the WHI has substantially
decreased the use of these treatments. The physiology
underlying VMS is complex and not fully understood, but
it is clear that alterations in noradrenergic and serotoner-
gic mechanisms during hypothalamic thermoregulation
are involved in their development. A significant unmet
need remains for menopause-related VMS treatment
options. Among women who are eligible for the treatment
of menopause-related VMS, 80% do not seek treatment,
receive inadequate counseling, or do not have access to
local medical aid [39]. The development of therapies that
specifically target VMS may provide high efficacy and
reduced risk of serious and potentially costly adverse
events, thus increasing the overall cost-effectiveness of
therapy.
List of abbreviations
BMI Body mass index
CAM Complementary alternative medication
CEE/MPA Conjugated estrogens plus medroxyprogester-
one acetate
HRQOL Health-related quality of life
HT Hormonal therapy
NA/EE Norethindrone acetate plus ethinyl estradiol
QALY Quality-adjusted life-years
QOL Quality of life
SF-36 36-Item Short Form Health Survey
SNRI Serotonin-norepinephrine reuptake inhibitor
SSRI Selective serotonin reuptake inhibitor
SWAN Study of Women's Health Across the Nation
UQOL Utian Quality of Life
VMS Vasomotor symptoms
WHI Women's Health Initiative
WHQ Women's Health Questionnaire
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